Amoy Diagnostics (SHE:300685) secured regulatory approval from China's medical products administrator for the expanded use of its cancer gene detection kit.
The Human 10-Gene Mutation detection kit can now detect EGFR exon 20 insertion mutations in plasma samples from non-small cell lung cancer patients, according to a Monday filing with the Shenzhen bourse.
Shares of the diagnostics company closed 1% higher Tuesday.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。